154 related articles for article (PubMed ID: 19543316)
1. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Haan S; Wüller S; Kaczor J; Rolvering C; Nöcker T; Behrmann I; Haan C
Oncogene; 2009 Aug; 28(34):3069-80. PubMed ID: 19543316
[TBL] [Abstract][Full Text] [Related]
2. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
5. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
6. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
7. SOCS-3 is involved in the downregulation of the acute insulin-like effects of growth hormone in rat adipocytes by inhibition of Jak2/IRS-1 signaling.
Ridderstråle M; Amstrup J; Hilton DJ; Billestrup N; Tornqvist H
Horm Metab Res; 2003 Mar; 35(3):169-77. PubMed ID: 12734778
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Bousquet C; Susini C; Melmed S
J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
[TBL] [Abstract][Full Text] [Related]
10. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Melzner I; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Barth TF; Leithäuser F; Möller P
Blood; 2005 Mar; 105(6):2535-42. PubMed ID: 15572583
[TBL] [Abstract][Full Text] [Related]
11. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT.
Kimura A; Naka T; Muta T; Takeuchi O; Akira S; Kawase I; Kishimoto T
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17089-94. PubMed ID: 16287972
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway.
Flores-Morales A; Fernández L; Rico-Bautista E; Umana A; Negrín C; Zhang JG; Norstedt G
Mol Endocrinol; 2001 Sep; 15(9):1471-83. PubMed ID: 11518796
[TBL] [Abstract][Full Text] [Related]
13. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.
Frantsve J; Schwaller J; Sternberg DW; Kutok J; Gilliland DG
Mol Cell Biol; 2001 May; 21(10):3547-57. PubMed ID: 11313480
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor.
Dif F; Saunier E; Demeneix B; Kelly PA; Edery M
Endocrinology; 2001 Dec; 142(12):5286-93. PubMed ID: 11713228
[TBL] [Abstract][Full Text] [Related]
15. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
[TBL] [Abstract][Full Text] [Related]
16. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
18. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
Lejeune D; Demoulin JB; Renauld JC
Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
[TBL] [Abstract][Full Text] [Related]
20. The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Hussein K; Brakensiek K; Buhr T; Schlué J; Wiese B; Kreipe H
Leuk Res; 2007 Jun; 31(6):799-803. PubMed ID: 17030374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
